Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

However, it is worth underlining that these outliers were distributed across clinicians’ estimates, that is, none of the clinicians repeatedly provided extreme values.Expert estimates for healthcare resource consumptionParameterMost likely (M) estimateLowest (L) estimateHighest (H) estimatemean (SD)mean (SD)mean (SD)Diagnosis # CT scan/year1.17 (0.75)0.83 (0.75)2.67 (1.03)# bone scan/year1.00 (0.63)0.50 (0.55)1.83 (0.75)# PET choline/year1.08 (0.80)0.50 (0.55)1.83 (0.75)# PET PSMA/year1.08 (0.80)0.50 (0.55)1.83 (0.75)Follow-up (visits and laboratory tests) # Outpatient visit/year5.17 (3.43)3.83 (2.23)7.67 (3.61)# PSA test/year5.00 (1.67)3.50 (1.52)8.67 (3.01)# Testosterone test/year3.83 (2.64)2.50 (2.17)6.33 (3.44)# Blood count test/year3.83 (4.02)2.00 (1.10)5.33 (4.46)# Blood glucose test/year3.33 (4.27)1.67 (1.21)4.50 (4.72)# Calcium test/year1.83 (1.17)1.17 (0.98)3.17 (2.04)# Vitamin D test/year1.83 (0.98)1.00 (0.89)3.17 (1.72)# Lipid profile test/year2.00 (2.28)0.83 (0.98)4.00 (4.15)# Creatinine test/year2.67 (1.63)1.50 (0.55)5.00 (3.69)# Electrolyte test/year2.17 (0.98)1.50 (0.55)3.67 (1.37)# Transaminases test/year3.67 (4.32)1.67 (1.03)5.00 (4.65)# Alkaline phosphatase test/year1.67 (1.63)1.17 (0.98)2.67 (2.16)# Bilirubin test/year3.00 (4.47)1.33 (0.82)4.17 (4.88)ADT treatment % Treated with buserelin1.67 (4.08)0.00 (0.00)10.17 (19.90)% Treated with goserelin1.67 (4.08)0.00 (0.00)10.17 (19.90)% Treated with leuprorelin50.00 (18.17)28.33 (17.22)66.67 (24.22)% Treated with triptorelin44.17 (8.01)25.00 (12.25)65.00 (24.29)% Treated with degarelix14.83 (9.17)9.50 (10.84)28.83 (17.89)% Yreated with bicalutamide15.83 (11.14)10.00 (8.94)36.67 (24.22)% Treated with flutamide0.00 (0.00)0.00 (0.00)1.67 (4.08)Serious AEs % Hospitalized for hematuria0.42 (0.49)0.17 (0.41)2.67 (3.78)% Hospitalized for urinary retentiona 5.67 (11.98)0.17 (0.41)8.67 (15.82)% Hospitalized for fractures0.96 (1.10)0.25 (0.42)1.67 (1.97)% Hospitalized for major cardiovascular eventsa 8.92 (15.34)1.00 (0.89)20.83 (25.53)The estimates provided by experts on the percentage of patients treated with ADT with severe urinary retention and major cardiovascular events are substantially higher than those reported in the trials from which these AEs were sourced.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy

Study design awaiting verification · International Journal of Technology Assessment in Health Care · 2023

Original publication title

Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy

Ludovica Borsoi; Oriana Ciani; Giuseppe Fornarini; Marco Oderda; Alessandro Sciarra; Damir Vetrini; Irene Luccarini

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This study estimated the direct healthcare costs of nmCRPC in Italy based on a mixed-methods approach. Delaying metastases may be a reasonable goal also from an economic standpoint. These findings can inform decision-making about treatments at the juncture between non-metastatic and metastatic prostate cancer disease.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

The management of non-metastatic castration-resistant prostate cancer (nmCRPC) is rapidly evolving; however, little is known about the direct healthcare costs of nmCRPC. We aimed to estimate the cost-of-illness (COI) of nmCRPC from the Italian National Health Service perspective.

Source: Objectives

Abstract: What methods does the paper describe?

Structured, individual qualitative interviews were carried out with clinical experts to identify what healthcare resources are consumed in clinical practice. To collect quantitative estimates of healthcare resource consumption, a structured expert elicitation was performed with clinical experts using a modified version of a previously validated interactive Excel-based tool, EXPLICIT (EXPert eLICItation Tool). For each parameter, experts were asked to provide the lowest, highest, and most likely value. Deterministic and probabilistic sensitivity analyses (PSA) were carried out to test the robustness of the results.

Source: Methods

Abstract: Results

Ten clinical experts were interviewed, and six of them participated in the expert elicitation exercise. According to the most likely estimate, the yearly cost per nmCRPC patient is €4,710 (range, €2,243 to €8,243). Diagnostic imaging (i.e., number/type of PET scans performed) had the highest impact on cost. The PSA showed a 50 percent chance for the yearly cost per nmCRPC patient to be within €5,048 using a triangular distribution for parameters, and similar results were found using a beta-PERT distribution.

Source: Results

Abstract: Conclusions

This study estimated the direct healthcare costs of nmCRPC in Italy based on a mixed-methods approach. Delaying metastases may be a reasonable goal also from an economic standpoint. These findings can inform decision-making about treatments at the juncture between non-metastatic and metastatic prostate cancer disease.

Source: Conclusions
Authors’ abstract

Objectives

The management of non-metastatic castration-resistant prostate cancer (nmCRPC) is rapidly evolving; however, little is known about the direct healthcare costs of nmCRPC. We aimed to estimate the cost-of-illness (COI) of nmCRPC from the Italian National Health Service perspective.

Methods

Structured, individual qualitative interviews were carried out with clinical experts to identify what healthcare resources are consumed in clinical practice. To collect quantitative estimates of healthcare resource consumption, a structured expert elicitation was performed with clinical experts using a modified version of a previously validated interactive Excel-based tool, EXPLICIT (EXPert eLICItation Tool). For each parameter, experts were asked to provide the lowest, highest, and most likely value. Deterministic and probabilistic sensitivity analyses (PSA) were carried out to test the robustness of the results.

Results

Ten clinical experts were interviewed, and six of them participated in the expert elicitation exercise. According to the most likely estimate, the yearly cost per nmCRPC patient is €4,710 (range, €2,243 to €8,243). Diagnostic imaging (i.e., number/type of PET scans performed) had the highest impact on cost. The PSA showed a 50 percent chance for the yearly cost per nmCRPC patient to be within €5,048 using a triangular distribution for parameters, and similar results were found using a beta-PERT distribution.

Conclusions

This study estimated the direct healthcare costs of nmCRPC in Italy based on a mixed-methods approach. Delaying metastases may be a reasonable goal also from an economic standpoint. These findings can inform decision-making about treatments at the juncture between non-metastatic and metastatic prostate cancer disease.

Publication and source details

Original title: Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy

Ludovica Borsoi; Oriana Ciani; Giuseppe Fornarini; Marco Oderda; Alessandro Sciarra; Damir Vetrini; Irene Luccarini

International Journal of Technology Assessment in Health Care · 2023

* Author for correspondence: Oriana Ciani, E-mail: oriana.ciani@unibocconi.it© The Author(s) 20232023The Author(s)https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. Janssen-Cilag Spa

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:05:44.736373+00:00

DOI: 10.1017/s0266462322003336 · PMC11574549